Back to Authors

Vital, Anne

Mayo Clinic

Centre Hospitalier Universitaire de Bordeaux

Citations 2

Further delineation of a rare recessive encephalomyopathy linked to mutations in GFER thanks to data sharing of whole exome sequencing data
Nambot, Sophie , Gavrilov, Dimitar , Thévenon, Julien , Bruel, Ange‐Line , Bainbridge, Matthew N. , Rio, Marlène , Goizet, Cyril , Rötig, Agnès , Jaeken, J., Niu, N., Xia, Fan , Vital, Anne, Houcinat, Nada, Mochel, Fanny , Kuentz, Paul , Lehalle, Daphné , Duffourd, Yannis , Rivière, Jean‐Baptiste , Thauvin-Robinet, Christel, Beaudet, Arthur L. , Faivre, Laurence , Nambot, S , Thevenon, J , Thauvin‐Robinet, Christel , Faivre, Laurence

Clinical Genetics | February 3, 2017 | Volume: 92 | Issue: 2 | Pages: 188-198

10.1111/cge.12985 Get It

BackgroundAlterations in GFER gene have been associated with progressive mitochondrial myopathy, congenital cataracts, hearing loss, developmental delay, lactic acidosis and respiratory chain deficiency in 3 siblings born to consanguineous Moroccan parents by homozygosity mapping and candidate gene approach (OMIM#613076). Next generation sequencing recently confirmed this association by the finding of compound heterozygous variants in 19‐year‐old girl with a strikingly similar phenotype, but this ultra‐rare entity remains however unknown from most of the scientific community.Materials and MethodsWhole exome sequencing was performed as part of a “diagnostic odyssey” for suspected mitochondrial condition in 2 patients, presenting congenital cataracts, progressive encephalomyopathy and hypotrophy and detected unreported compound heterozygous variants in GFER.ResultsThanks to an international data sharing, we found 2 additional patients carrying compound heterozygous variants in GFER. Reverse phenotyping confirmed the phenotypical similarities between the 4 patients. Together with the first literature reports, the review of these 8 cases from 4 unrelated families enables us to better describe this apparently homogeneous disorder, with the clinical and biological stigmata of mitochondrial disease.ConclusionThis report highlights the clinical utility of whole exome sequencing and reverse phenotyping for the diagnosis of ultra‐rare diseases and underlines the importance of a broad data sharing for accurate clinical delineation of previously unrecognized entities.
Posttranscriptional Regulation of PER1 Underlies the Oncogenic Function of IREα
Pluquet, Olivier , Dejeans, Nicolas, Bouchecareilh, Marion , Lhomond, Stéphanie , Pineau, Raphaël , Higa, Arisa, Delugin, Maylis, Combe, Chantal, Loriot, Sandrine, Cubel, Gaëlle, Dugot‐Senant, Nathalie, Vital, Anne, Loiseau, Hugues , Gosline, Sara J.C. , Taouji, Saı̈d , Hallett, Michael , Anderson, Keith, Rosenbaum, Jean , Saltel, Frédéric , Fernández-Zapico, Martín E. , Chevet, Éric , Loriot, Sandrine, Sarkaria, Jann N. , Wu, Wenting , Rodríguez, Fausto J. , Chevet, Eric

Cancer Research | June 11, 2013 | Volume: 73 | Issue: 15 | Pages: 4732-4743

10.1158/0008-5472.can-12-3989 Get It

Abstract Growing evidence supports a role for the unfolded protein response (UPR) in carcinogenesis; however, the precise molecular mechanisms underlying this phenomenon remain elusive. Herein, we identified the circadian clock PER1 mRNA as a novel substrate of the endoribonuclease activity of the UPR sensor IRE1α. Analysis of the mechanism shows that IRE1α endoribonuclease activity decreased PER1 mRNA in tumor cells without affecting PER1 gene transcription. Inhibition of IRE1α signaling using either siRNA-mediated silencing or a dominant-negative strategy prevented PER1 mRNA decay, reduced tumorigenesis, and increased survival, features that were reversed upon PER1 silencing. Clinically, patients showing reduced survival have lower levels of PER1 mRNA expression and increased splicing of XBP1, a known IRE-α substrate, thereby pointing toward an increased IRE1α activity in these patients. Hence, we describe a novel mechanism connecting the UPR and circadian clock components in tumor cells, thereby highlighting the importance of this interplay in tumor development. Cancer Res; 73(15); 4732–43. ©2013 AACR.